Why U.S.-traded shares of Novartis fell 18 cents to $56.28 in morning trading.?

Mixed Performance Ahead for Credit Sector Consumer defensive should perform admirably while our enthusiasm for the industrials sector has cooled. Biotechs & FDA Decisions (SMB, 05/05/10)

Fibrocell Receives FDA Approval for LaViv Updated with more information, stock reaction. EXTON, Penn. (TheStreet) — U.S. regulators approved Wednesday Fibrocell Sciences’ Laviv, a personalized cell-based dermal filler, according to an FDA spokeswoman. Fibrocell will market LaViv for the treatment (smoothing out) of nasolabial fold wrinkles — those are the skin folds that run from [...]